Irwin, Michael H.Moos, Walter H.Faller, Douglas V.Steliou, KostaPinkert, Carl A.2020-05-142016-05-01Michael H Irwin, Walter H Moos, Douglas V Faller, Kosta Steliou, Carl A Pinkert. 2016. "Epigenetic treatment of neurodegenerative disorders: Alzheimer and Parkinson diseases." Drug Development Research, Volume 77, Issue 3, pp. 109 - 123. https://doi.org/10.1002/ddr.212940272-43911098-2299https://hdl.handle.net/2144/40864Please note: this work is permanently embargoed in OpenBU. No public access is forecasted for this item. To request private access, please click on the locked Download file link and fill out the appropriate web form.In this review we expand our discussion of epigenetic-driven methods for treating neurodegenerative disorders associated with mitochondrial dysfunction, focusing on carnitinoid antioxidant-histone deacetylase inhibitors that show an ability to reinvigorate synaptic plasticity and protect against neuromotor decline in vivo. Aging remains a major risk factor in patients who progress to dementia, a clinical syndrome typified by decreased mental capacity, including impairments in memory, language skills, and executive function. Energy metabolism and mitochondrial dysfunction are viewed as determinants in the aging process that may afford therapeutic targets for a host of disease conditions, the brain being primary in such thinking. Mitochondrial dysfunction is a core feature in the pathophysiology of both Alzheimer and Parkinson diseases and rare mitochondrial diseases. The potential of new therapies in this area extends to glaucoma and other ophthalmic disorders, migraine, Creutzfeldt–Jakob disease, post-traumatic stress disorder, systemic exertion intolerance disease, and chemotherapy-induced cognitive impairment. An emerging and hopefully more promising approach to addressing these hard-to-treat diseases leverages their sensitivity to activation of master regulators of antioxidant and cytoprotective genes, antioxidant response elements, and mitophagy.p. 109 - 123en-USScience & technologyLife sciences & biomedicineChemistry, medicinalAlzheimerCarnitineHistone deacetylaseHistone deacetylase inhibitorsNeurodegenerationPMX-500Reactive oxygen speciesAlpha-lipoic acidTraumatic brain injuryAcetyl-l-carnitineMitochondria-targeted antioxidantPyruvate-dehydrogenase complexMild cognitive impairmentAge-related diseasesTherapeutic targetOxidative stressParkinsonButyrateEpigeneticLipoic acidMitochondrial dysfunctionPost-traumatic stress disordersAntioxidantsEpigenesis, geneticHumansMitochondriaNeuronal plasticityParkinson diseaseAlzheimer diseaseTreatment outcomeAntioxidantPMX-550Pharmacology & pharmacyPharmacology and pharmaceutical sciencesArticle10.1002/ddr.212940000-0002-5530-3194 (Steliou, Kosta)62170